Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MEI, ESC, IFN, PWRM, MSLP - Stock Watch From




Power3 Medical Products, Inc. (OTC.BB:PWRM) is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.

Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

Recently, the Company announced that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed soon.

"We are very excited to be acquiring Rozetta-Cell Life Sciences," stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. "Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."


MusclePharm Corporation (OTCBB:MSLP) one of the fastest growing nutritional supplement companies in the United States, has been invited to present at the upcoming HIV DART 2010: Frontiers in Drug development for Antiretroviral Therapies Conference being held from December 7-10, 2010 in Los Cabos, Mexico.

This innovative conference, HIV DART 2010, will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection. This brings leaders in the research community together to advance the medical communities knowledge of the ongoing drug development processes in antiretroviral research.

At this year's HIV DART 2010 Conference, MusclePharm will present its results on the use of its product, Recon, in HIV patients. Early results show that Recon may help prevent the onset of wasting syndrome by facilitating the growth and maintenance of muscle mass in people living with HIV, which has been associated with antiretroviral drug resistance.

MusclePharm's President, Cory Gregory stated, "We started MusclePharm to enable people of all fitness levels to maintain and improve their general fitness through a daily nutritional supplement regimen. We are very pleased to have our work accepted by such a prestigious group of physicians and researchers focused on improving the lives of people with the HIV virus."

Mr. Gregory continued, "This conference is well known for its prominent list of attendees, which includes the greatest minds HIV research has to offer. The fact that the scientific committee at HIV DART 2010 viewed our work as significant and ground breaking shows the scientific strength of our products and great promise for the future use of therapeutic nutritional supplements for the treatment of HIV disease."

Recon contains important amino acids, assisting in reaching the higher levels of nutrition required for people living with HIV. MusclePharm's Recon Nutritional Supplement is easily digestible, helps the absorption of amino acids and proteins. It contains essential minerals, digestive enzymes, Glutamine and other metabolic agents that maximize recovery, protein synthesis and endurance.


India Fund, Inc. (NYSE:IFN) a closed-end management investment company that seeks long-term capital appreciation by investing primarily in equity securities of Indian companies, announced unaudited results for the nine months ended September 30, 2010. For the nine months ended September 30, 2010, the Fund’s net realized gains were $149,882,706 and the net change in unrealized gains was $144,643,749. Net investment income for the nine months ended September 30, 2010 was $873,281. For the same nine month period ended September 30, 2009, the Fund’s net realized losses and net change in unrealized gains were $18,615,494 and $554,396,536, respectively. Net investment income was $850,424.

India Fund, Inc. is a close ended equity mutual fund launched by The Blackstone Group. It is managed by Blackstone Asia Advisors L.L.C. The fund invests in public equity markets of India. It seeks to invest in stocks of small-cap, mid-cap and large-cap companies. The fund employs a quantitative and fundamental analysis with a bottom-up stock picking and asset allocation approach to create its portfolio.


Emeritus Corp. (NYSE:ESC) announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share. 4,000,000 shares of common stock will be sold by Emeritus and 1,000,000 shares will be sold by the selling shareholders. Emeritus has granted the underwriters a 30-day option to purchase at the public offering price up to an additional 750,000 shares to cover overallotments, if any. Emeritus intends to use its net proceeds from the offering to pay the $13 million cash portion of the purchase price of its previously announced acquisition of the assets of Randall Weston and Weston Group, Inc., to make an aggregate repayment of $14.2 million of the outstanding principal of two loans owed to Ventas Realty, Limited Partnership, and for other general corporate purposes, including facility developments and acquisitions. Emeritus will not receive any proceeds from the sale of shares by the selling shareholders.

Emeritus Corporation operates senior living communities that provide assisted living, and Alzheimer’s and dementia care services to senior citizens in the United States. Its communities provide residential housing alternatives, including independent living, assisted living, specialized memory care, and skilled nursing services.


Methode Electronics Inc. (NYSE:MEI) a global developer of custom engineered and application specific products and solutions, has been awarded a next generation integrated center stack program for multiple General Motors vehicle platforms. The center stacks will be featured on certain vehicles starting in model year 2013, and are expected to have a five-year program life. Center stack production will begin during Methode’s fiscal year 2013 and is expected to represent over $100 million in revenue per year starting in fiscal year 2014. Actual revenue will depend on a number of factors, including consumer demand for General Motors’ vehicles.

Methode Electronics, Inc. manufactures component devices worldwide. The company’s products utilize electronic and optical technologies to control and convey signals through sensors, interconnections, and controls. It operates in four segments: Automotive, Interconnect, Power Distribution, and Other.




Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP).

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).